Is There a Role for Surgery for Microprolactinomas?

ABSTRACT

The neurosurgical and endocrinologic treatment of prolactinomas has undergone significant advances in the past three decades. Because of medical progress, we are now confronted with two safe, effective approaches for treating prolactinomas. Transsphenoidal surgery for microprolactinomas carries a 90% cure rate while incurring minimal risks, and offers the only opportunity for endocrinologic and oncologic cure. Alternatively, treatment with bromocriptine and other dopaminergic agents also results in effective chemical control in greater than 90% of cases but requires lifelong treatment. Pharmacologic control of microprolactinomas remains the mainstay of treatment, but surgical indications include patients intolerant of medical treatment, failing medical therapy, and desiring pregnancy. Young patients wishing to avoid lifelong medical treatment may also be operative candidates. In these situations. surgery is a vital adjunct in the management of prolactinoma-secreting microadenomas.

KEYWORDS

Prolactinoma - transsphenoidal surgery - bromocriptine - pituitary adenoma

REFERENCES

• 1 Cushing H. The Pituitary Body and Its Disorders.  Philadelphia, PA: JB Lippincott 1912
• 2 Thapar K, Laws E. Pituitary tumors. In: Kaye A, Laws E, eds. Brain Tumors Edinburgh, Scotland: Churchill Livingstone 1995 0: 759-773
• 3 Costello R. Subclinical adenoma of the pituitary gland.  Am J Path . 1936;  12 205-216
• 4 Kovacs K, Horvath H. Pathology of pituitary tumors.  Endocrinol Metab Clin . 1987;  16 529-551
• 5 Parent D, Bebin J, Smith R. Incidental pituitary adenomas.  J Neurosurg . 1981;  54 228-230
• 6 Evans W, Thorner M. Mechanisms for hypogonadism in hyperprolactinemia.  Semin Reprod Endocrinol . 1984;  2 9-22
• 7 Weiss M. Pituitary tumor: an endocrinological and neurosurgical challenge.  Clin Neurosurg . 1992;  39 114-122
• 8 Touraine P, Plu-Bureau G, Beji C, Mauvais-Jarvis P, Kuttenn F. Long-term follow-up of 246 hyperprolactinemic patients.  Acta Obstet Gynecol Scand . 2001;  80 162-168
• 9 Weiss M, Teal J, Gott P. Natural history of microprolactinomas: six-year follow-up.  Neurosurgery . 1983;  12 180-183
• 10 Weiss M. Medical and surgical management of functional pituitary tumors.  Clin Neurosurg . 1981;  28 374-383
• 11 Katz E, Schran H, Adashi E. Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy.  Obstet Gynecol . 1989;  73 517-519
• 12 Orrego J, Barkan A. Pituitary disorders: drug treatment options.  Drugs . 2000;  59 93-106
• 13 Pinzone J, Katznelson L, Danila D, Pauler D, Miller C, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men.  J Clin Endocrinol Metab . 2000;  85 3053-3057
• 14 Webster J, Piscitelli G, Polli A. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea.  N Engl J Med . 1994;  331 904-909
• 15 Di Sarno A, Landi M, Marzullo P. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.  Clin Endocrinol . 2000;  53 53-60
• 16 Molitch M. Management of prolactinomas during pregnancy.  J Reprod Med . 1999;  44 S1121-S1126
• 17 Jewelewicz R, Vande Wiele R. Clinical course and outcome of pregnancy in twenty-five patients with pituitary microadenomas.  Am J Obstet Gynecol . 1980;  136 339-343
• 18 Vician L, Shupnik M, Gorski J. Effects of estrogen on primary ovine pituitary cell cultures: stimulation of prolactin secretion, synthesis and prolactin messenger ribonucleic acid levels.  Endocrinology . 1979;  104 736-743
• 19 Molitch M. Medical treatment of prolactinomas.  Endocrinol Metab Clin North Am . 1999;  28 143-169
• 20 Little M, Shalet S, Beardwell C. Hypopituitarism following external radiotherapy for pituitary tumors in adults.  J Med . 1989;  70 145-160
• 21 Pan L, Zhang N, Wang E, Wang B, Dai J, Cai P. Gamma knife radiosurgery as a primary treatment for prolactinomas.  J Neurosurg . 2000;  93 S10-S13
• 22 Landolt A, Lomax N. Gamma knife radiosurgery for prolactinomas.  J Neurosurg . 2000;  93 S14-S18
• 23 March C, Kletzky O, Davajan V. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas.  Am J Obstet Gynecol . 1981;  139 835-844
• 24 Shimon I, Hinton D, Weiss M, Melmed S. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness.  Clin Endocrinol . 1998;  48 23-29
• 25 Sakamoto H, Mori M, Taira M. Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa.  Proc Natl Acad Sci USA . 1986;  83 3997-4001
• 26 Velcich A, Delli Bovi P, Mansukhani A, Ziff E, Basilico C. Expression of the K-fgf proto-oncogene is repressed during differentiation of F9 cells.  Oncogene Res . 1989;  5 31-37
• 27 Adelaide J, Mattei M, Marics I. Chromosomal localization of the hst oncogene and its co-amplification with the int.2 oncogene in human melanoma.  Oncogene . 1988;  2 413-416
• 28 Neal J, Weiss M. Management of prolactin-secreting pituitary adenomas.  West J Med . 1990;  153 546-547
• 29 Weiss M. Treatment options in the management of prolactin-secreting pituitary tumors.  Clin Neurosurg . 1986;  33 547-552
• 30 Ozgen T, Oruckaptan H, Ozcan O, Acikgoz B. Prolactin secreting pituitary adenomas: analysis of 429 surgically treated patients, effects of adjuvant treatment modalities and review of the literature.  Acta Neurochir . 1999;  141 1287-1294
• 31 Couldwell W, Weiss M. Defining postoperative values for successful resection of prolactinomas.  J Neurosurg . 1996;  85 990-991
• 32 Ciric I, Ragin A, Baumgartner C. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience.  Neurosurgery . 1997;  40 225-237
• 33 Zacur H. Indications for surgery in the treatment of hyperprolactinemia.  J Reprod Med . 1999;  44 S1127-S1131
• 34 Landolt A. Surgical treatment of pituitary prolactinomas: postoperative prolactin and fertility in seventy patients.  Fertil Steril . 1981;  35 620-625
• 35 Weiss M, Wycoff R, Yadley R, Gott P, Feldon S. Bromocriptine treatment of prolactin-secreting tumors: surgical implications.  Neurosurgery . 1983;  12 640-642
• 36 Pellegrini I, Rasolonjanahary R, Gunz G. Resistance to bromocriptine in prolactinomas.  J Clin Endocrinol Metab . 1989;  69 500-509